ASX Release SUDA LTD: INVESTOR PRESENTATION
|
|
- Claude Gregory
- 5 years ago
- Views:
Transcription
1 ACN ASX Release SUDA LTD: INVESTOR PRESENTATION PERTH, AUSTRALIA 15 August 2017: SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, today announces that Mr. Stephen Carter, Managing Director and CEO, and Mr. Michael Stewart, Chairman, are meeting with investors, brokers and media in Melbourne and Sydney from August The presentation follows. Further information: STEPHEN CARTER CHIEF EXECUTIVE OFFICER / MANAGING DIRECTOR SUDA LTD Tel: sjcarter@sudaltd.com.au NOTES TO EDITORS: About SUDA LTD SUDA LTD (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA s product pipeline includes ZolpiMist, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. SUDA s most advanced development-stage product, ArTiMist, is a novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist was shown to be superior to intravenous quinine. Other products in development include oral sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction and pre-procedural anxiety. For more information, visit ASX Release No August 2017 Page 1 of 1
2 A Revolution in drug delivery Stephen Carter Chief Executive Officer Michael Stewart Chairman August 2017
3 Disclaimer The purpose of the presentation is to provide an update of the business of SUDA LTD (ASX:SUD) [ SUDA ]. These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by SUDA and should not be relied upon as an independent source of information. Please contact SUDA and/or refer to the Company's website for further information. The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside SUDA s control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and SUDA s current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution. This presentation should not be relied on as a recommendation or forecast by SUDA. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction. 2
4 WHAT WE DO Develop new technology for rapid and efficient absorption of drugs directly into the bloodstream through the oral mucosa (mouth lining) we make money through transactions by out-licensing our products with upfront & milestone payments & are developing a sustainable income through royalty payments 3
5 PATENTS UNDERPIN OUR STORY > 300 Drugs-Patent portfolio ( ) ArTiMist-Composition and Use Patents (2027) Sildenafil patents (2032) New Hydrotrope Platform Technology Patent (2037) Multiple Trademarks OroMist, Zolpimist, DuroMist, ArTiMist Proprietary trade secrets
6 World class products + patents to drive growth
7 FOUR YEARS OF EXPLOSIVE GROWTH PATENTS PRODUCTS TRANSACTIONS 0 >30 1 > VALUATION $20m?
8 DRIVEN BY LEADING EXPERTS Including Chief Technical Officer Dr Carol Worth B.Sc (Jt Hons), MSc. PhD C.Chem FRSC, C.Chem MRACI Development Chemist who has laid foundations for new IP to be build into Hydrotropes project Head of Projects Dr Deborah Cooper BSc (Hons), ARCS, MSc, PhD (Cantab) Biotech professional with 25 years experience expert in Cell Biology/Immunology, Clinical, Manufacturing, Product Development and Project Management
9 PATENT PORTFOLIO ATTRACTS PFIZER OroMist IP covers ~300 compounds Our Hydrotrope technology enhances absorption and permeation Specialise in composition formulation, stability system & taste-masking system Pfizer contracted SUDA to access our IP
10 DELIVERY SYSTEM IMPROVES DRUG EFFECTIVENESS Absorption of molecules via oral mucosa Onset of action Drug bioavailability Dosage concentration Concentration Receptor Cell ug/ml Potential side effects 0 60 min (Time) 200 Approx. 10x increase SUD-003 in absorption 1st Gen with new-generation SUD-003 New SUD-003 Gen vs. 1st generation at 60-minute time-point in ex-vivo buccal (cheek) membrane model 9
11 Innovative patents + products improve drug delivery
12 PRODUCTS Product Candidate, Selection Criteria Distinct benefits for the patients Unique Selling Point Improved onset of action and bio-availability Reduced side effects Low risk regulatory pathway Competitive commercial advantage Potential global sales footprint Monopoly through patent protection 11
13 MIDAZOLAM (SUD005) Clinical win + large market Midazolam is used to treat epileptic seizures in large global market Delivery of Midazolam via a SUDA s oral spray would offers clinical advantages and commercial opportunities Patients present with strong muscular convulsion Tablets or injections, both present difficulties in administration Buccolam (current treatment) - marketed by Shire Pharmaceuticals. Launched 2012, generating strong sales (US$300m) & growth + 80% pa. Administration of Buccolam still presents difficulties for nursing staff & doctors 12
14 GROWING PRODUCT PIPELINE Product API Pre-clinical Clinical Approval Mkt Size Partnerships *ZolpiMist Zolpidem Insomnia USA $2.1bn Eddingpharm (China) TEVA (Brazil, Mexico, Chile) ArtiMist Artemether Malaria >$500m SUD-002 Ondansetron Chemotherapy induced nausea & vomiting $2.5bn Kwang Dong (Korea) SUD-001 Sumatriptan Migraine headache $3.2bn DuroMist Sildenafil Erectile dysfunction $4.1bn SUD-004 Sildenafil PAH $2.7bn SUD-005 Midazolam Epileptic seizures >$300m SUD-0XX Anagrelide Cancer >$1bn * SUDA has an exclusive license to ZolpiMist in all countries excluding USA and Canada 13
15 Transactions with major pharmas validate our IP
16 CHINA OPENS ITS DOORS ZolpiMist Eddingpharm agreement in China Exclusive license to develop and commercialise ZolpiMist in China Eddingpharm is large Chinese pharma company covering more than 3,000 hospitals in 29 provinces Total value of deal could exceed $34m - Upfront payment ~$0.4m - Registration milestone ~$0.3m - Product supplied by SUDA - Escalating tiered royalties 15
17 Eddingpharm CEO: An estimated 45% of Chinese, 590m people, have problems with sleep. ZolpiMist is an excellent fit with our current infrastructure and strategy.
18 LATIN AMERICA FOLLOWS ZolpiMist Teva agreement in Latin America Exclusive license to develop and commercialise ZolpiMist in Brazil, Mexico and Chile, plus option-to-license in Argentina, Israel and Australia Teva is top-20 Pharma and world s largest generics company Total value of deal could exceed $55m - Upfront payment of ~$0.4m - Milestones of ~$2.3m - Product supplied by SUDA - Double-digit royalties 17
19 Teva, the world s largest generics company, has the commercial scale to maximise sales of ZolpiMist. Potentially very lucrative for SUDA based on royalties and supply
20 TRANSACTIONS Feasibility and option agreement with Pfizer Consumer Healthcare Fee-for-service agreement to formulate two well known over-thecounter drugs into oral sprays Pfizer has option to negotiate global commercial licence (upfront, milestones and royalties) 19
21 OTHER TRANSACTIONS Service business Co-development Added-value development services to companies seeking to formulate APIs into proprietary oro-mucosal sprays with unique advantages Formulation services for Rx, OTC, veterinary, vitamin and nutraceutical oral sprays Pharmaceutical development laboratory carrying out world class research Australian Registered Research Agency since 2016 In 2017, accreditation upgraded to highest international standard of ISO 9001:2015 Targeting Australian TGA GMP licence in 2017 SUDA is a Registered Research Provider 20
22 Undervalued with earnings growth
23 PROJECTED REVENUE GROWTH 30,000,000 25,000,000 20,000,000 $24m 15,000,000 10,000,000 5,000,000 $9.3m $15.6m total receipts
24 SUD Valuation/Share Price (A$) Valuation/Market Capitalisation (A$m) $0.300 NDF Valuation Summary Upper Case, 25cps $350.0 $0.250 $0.200 Mid-case represents >900% upside from current share price Mid Case, 17cps $300.0 $250.0 $200.0 $0.150 $0.100 Lower Case, 9cps $150.0 $100.0 $0.050 SUD Share Price, 1.7cps $50.0 $0.000 Lower Case Mid Case Upper Case SUD Share Price $0.0
25 Key data & financial snapshot Corporate key data ASX Code SUD:AU Current share price (Australian $) $ week range $0.015-$0.028 Average volume (30-day) 1.3 million Market cap $22 million Financials Receipts (Fcst) $9,300,000 $15,600,000 $24,000,000 Net operating Cash-outflows ($10,600,000) ($13,400,000) ($15,100,000) Net Cash at 30 June $560,000 $2,700,000 $14,100,000 Shares on issue Convertible Notes 1,220 million $2.0 million convertible to 84 million shares 24
26 Board & Senior Management Chairman Michael Stewart MD/ CEO Stephen Carter BSc CFO/Director & Co.Sec Joseph Ohayon CA, MBA Chief Business Officer Nick Woolf MA (Oxon) FCCA Strong foundation in capital markets and experience in international aid 30 years experience in drug development including cancer drugs. Delta West/Pfizer, Solbec Worked in healthrelated industries for over 15 years and held several CFO roles and directorships 15 years industry experience in international business development. Previously at Phylogica and Oxford BioMedica
27 NEXT STEPS ZolpiMist master license deal in Europe Further partnering deals with SUDA s other candidates Monetisation of ArTiMist Expansion of Pfizer collaboration Early sales success for TEVA with ZolpiMist Expansion of TEVA markets Approval of ZolpiMIst in Australia and Europe
28 SUDA IS GOING PLACES Growing world class patents and products Transactions with major pharmas validate Suda Leading technical team to drive innovation Strong earnings growth over next five years China could provide x factor in earnings growth
For personal use only
ACN 090 987 250 ASX Release SUDA LTD: INVESTOR PRESENTATION PERTH, AUSTRALIA 20 September 2016: a leader in oro-mucosal drug delivery, today announces that Mr. Stephen Carter, Managing Director and CEO,
More informationDrug delivery through the oral mucosa. Stephen Carter - Chief Executive Officer Nick Woolf Chief Business Officer. April 2018
Drug delivery through the oral mucosa Stephen Carter - Chief Executive Officer Nick Woolf Chief Business Officer April 2018 Disclaimer The purpose of the presentation is to provide an update of the business
More informationFor personal use only
ACN 090 987 250 ASX Release SUDA LTD: INVESTOR PRESENTATION PERTH, AUSTRALIA 25 February 2016: SUDA LTD (ASX: SUD), a leader in oro- mucosal drug delivery, today announces that Mr. Stephen Carter, Chief
More informationPhylogica 2016 Broker Meets Biotech (PYC:ASX) Developing new drugs against intracellular cancer targets beyond the reach of existing therapies
Phylogica 2016 Broker Meets Biotech (PYC:ASX) Developing new drugs against intracellular cancer targets beyond the reach of existing therapies Disclaimer The purpose of the presentation is to provide an
More informationInvestor Presentation
ASX:THC B u i l d i n g a M e d i c i n a l C a n n a b i s B u s i n e s s Investor Presentation November 2017 DISCLAIMER The material in this presentation (material) is not and does not constitute an
More informationFor personal use only
ASX RELEASE (23 rd March 2018) AGM PowerPoint Presentaion In accordance with the requirements of Listing Rule 3.1 we submit the attached material being distributed at the Company s Annual General Meeting
More informationDrug delivery through the oral mucosa. Stephen Carter Chief Execu;ve Officer Nick Woolf Chief Business Officer. April 2014
Drug delivery through the oral mucosa Stephen Carter Chief Execu;ve Officer Nick Woolf Chief Business Officer April 2014 Overview SUDA (ASX: SUD) is a drug delivery company commercialising lowrisk pharmaceu>cals
More informationASX Release PROGRAM UPDATE: ANAGRELIDE
ACN 090 987 250 ASX Release PROGRAM UPDATE: ANAGRELIDE Key points: Platelets are involved in cancer progression A reduction of platelets can help prevent tumour growth and metastasis Anagrelide prevents
More informationInvestment in MGC Pharmaceuticals
Investment in MGC Pharmaceuticals Investor Presentation May 2015 Disclaimer This presentation has been prepared by Erin Resources Limited ( Company ). It does not purport to contain all the information
More informationDR.NEIL FRAZER CHIEF EXECUTIVE OFFICER & MANAGING 1
DR.NEIL FRAZER CHIEF EXECUTIVE OFFICER & MANAGING DIRECTOR @Dr_Neil_Frazer 1 IMPORTANT NOTICE The purpose of the presentation is to provide an update of the business of OncoSil Medical Ltd (ASX:OSL). These
More informationShareholder Presentation Annual Meeting 2018
Shareholder Presentation Annual Meeting 2018 FY 18 HIGHLIGHTS Strong sales growth of 2 nd Gen TruScreen to China commenced during 4 th quarter. (50% of the year s sales were generated in the fourth quarter)
More informationWednesday 26 th November 2008 The ASX Company Announcements office: Chairman s AGM Address
Advanced Molecular Diagnostic Systems The Walter and Eliza Hall Biotechnology Centre, 4 Research Avenue, La Trobe R&D Park, Bundoora, Victoria 3083 T: +61 (0)3 9345 2127 F: +61 (0)3 9345 2242 Wednesday
More informationPROACTIVE INVESTOR PRESENTATION
www.thcl.com.au ASX RELEASE (16 th May 2017) PROACTIVE INVESTOR PRESENTATION The Hydroponics Company Limited (ASX: THC) is pleased to advise that Dr Andrew Beehag, Chief Executive Officer of Canndeo Limited,
More informationZacks Small-Cap Research
Zacks Small-Cap Research Sponsored Impartial - Comprehensive August 29, 2018 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Opiant Pharmaceuticals,
More informationASX ANNOUNCEMENT CELLMID CEO TO PRESENT AT WHOLESALE INVESTOR CONFERENCE
ASX ANNOUNCEMENT CELLMID CEO TO PRESENT AT WHOLESALE INVESTOR CONFERENCE SYDNEY, Tuesday, 20 November 2012: Cellmid Limited (ASX: CDY) CEO, Maria Halasz, will present today at the Wholesale Investor Conference,
More informationINVESTOR PRESENTATION
INVESTOR PRESENTATION May 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities regulation.
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More informationTamsulosin Hydrochloride 0.4 mg Capsule
Tamsulosin Hydrochloride 0.4 mg Capsule, Tamsulosin Hydrochloride 0.4 mg Capsule India, Tamsulosin Hydrochloride 0.4 mg Capsule manufacturers India, side effects Tamsulosin Hydrochloride 0.4 mg Capsule
More informationForward-Looking Statements
Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.
More informationFor personal use only ANNUAL GENERAL MEETING PRESENTATION ZELDA THERAPEUTICS NOVEMBER ASX:ZLD
ANNUAL GENERAL MEETING PRESENTATION NOVEMBER 2017 ZELDA THERAPEUTICS ASX:ZLD www.zeldatherapeutics.com Disclaimer and Important Notice Disclaimer This presentation has been prepared by Zelda Therapeutics
More informationAnnual General Meeting
Annual General Meeting November 2017 ASX: MEB OTCQB: MDBIF Medibio Limited 2016 2 DISCLAIMER FORWARD LOOKING STATEMENTS Accordingly, these slides and the information they contain should be read in conjunction
More informationInvestor presentation. Bioshares Biotech Summit July 2017
Investor presentation Bioshares Biotech Summit 2017 22 July 2017 1 Disclaimer Some of the information in this presentation may refer to Dimerix Limited ( Dimerix or the Company ) based on information available
More informationAXIM Biotechnologies Reports Year End 2017 Results
March 19, 2018 AXIM Biotechnologies Reports Year End 2017 Results NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC:AXIM), a world leader in cannabinoid research
More informationFor personal use only
ACN 090 987 250 ASX Release SUDA LTD: INVESTOR ROAD SHOW PRESENTATION PERTH, AUSTRALIA 24 : SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, today announces that Mr. Stephen Carter, Managing
More informationAdvancing Pancreatic & Liver Cancer Treatment
ASX.OSL Advancing Pancreatic & Liver Cancer Treatment Australian Biotech Invest 2017 October 24 th Melbourne 1 Important notice This Presentation has been prepared by Ltd (ASX:OSL) (OncoSil or the Company)
More informationEmisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results
August 11, 2008 Emisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results Conference Call/Webcast to be Held Monday, August 11 at 10:00 AM EDT CEDAR KNOLLS, N.J., Aug 11, 2008 /PRNewswire-FirstCall
More informationInvestor Presentation
Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities
More informationMDxHealth. Excellent Buy Opportunity. Research Note.
Research Note MDxHealth Excellent Buy Opportunity Chief Research Analyst Marcel Wijma MSc +1 (917) 460 6185 (US) +31 (6) 8489 2954 (NL) m.wijma@leeuwenhoeck.com http://www.leeuwenhoeck.com Date: 29 February
More informationOWC PHARMACEUTICALS RESEARCH OTCQB:OWCP
OWC PHARMACEUTICALS RESEARCH OTCQB:OWCP Disclaimer This document details business information of OWC Pharmaceuticals Research Corp and/or our wholly-owned Israeli subsidiary, One World Cannabis Ltd. (collectively,
More informationUniversal Biosensors, Inc.
Universal Biosensors, Inc. ARBN 121 559 993 Buchan Three Tickers Presentation 18 th September 2013 1 Important Disclaimer This presentation is intended to provide a general outline only and is not intended
More informationSumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company)
December 21, 2016 Sumitomo Dainippon Pharma Co., Ltd. Sumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company) Sumitomo Dainippon Pharma Co., Ltd. (Head office: Osaka,
More informationA world leader in allergy immunotherapy. Jefferies Global Healthcare Conference, London : 19 November 2014 : Flemming Pedersen, CFO & EVP
A world leader in allergy immunotherapy ALK at a glance Leading allergy immunotherapy (AIT) specialist AIT: Treats the root cause of allergy Products in all areas of AIT ALK has 33% of the global AIT market
More informationNOXOPHARM POSTS CORPORATE PRESENTATION AHEAD OF CONFERENCE ASX: NOX. Presentation at Singapore Investor Conference Review of first year of operation
Date 8 August 2017 Sydney, Australia ASX: NOX Noxopharm Limited ABN 50 608 966 123 Registered Office: Suite 1 Level 6 50 Queen St Melbourne VIC 3000 Australia Operations Office: Suite 3 Level 4 828 Pacific
More informationFor personal use only
Australian Securities Exchange Limited Companies Announcements Office SYDNEY 4 April, 2012 New Australian Drug Developer Lists on ASX Key points Growth-focused Australian drug and therapeutic development
More informationValneva Reports Strong 2017 Revenues Driven by Double Digit Product Sales Growth
Valneva Reports Strong 2017 Revenues Driven by Double Digit Product Sales Growth Strong sales performance in 2017 (unaudited) Total revenues of 109.8 million in 2017 (2016-97.9 million) representing year-on-year
More informationDS-8201 Strategic Collaboration
DS-8201 Strategic Collaboration DAIICHI SANKYO CO., LTD George Nakayama Chairman and CEO March 29, 2019 Forward-Looking Statements Management strategies and plans, financial forecasts, future projections
More informationFor personal use only
Prima BioMed Annual General Meeting CEO Presentation November 25, 2016 ASX:PRR; NASDAQ:PBMD Marc Voigt 1 Notice: Forward Looking Statements The purpose of the presentation is to provide an update of the
More informationDeveloping & Commercializing Targeted Small Molecule Drugs in Cancer
Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationPhotocure ASA Executing the Strategy
Photocure ASA Executing the Strategy DECEMBER 6, 2012 KJETIL HESTDAL, CEO Disclaimer The information included in this Presentation contains certain forward-looking statements that address activities, events
More informationInvestor Presentation June 2012 NASDAQ: CEMI
Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act
More informationInvestor Presentation Post-Interim Results Update. September 2011
Investor Presentation Post-Interim Results Update September 2011 Disclaimer This presentation contains general information about the company s activities current as at 2 September 2011. It is provided
More informationAugust 7, Q Financial Results
August 7, 2018 Q2 2018 Financial Results 1 Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer
More informationXXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology
Company Update Industrial & Consumer Technology (XXII - $2.81 - Buy) COMPANY NOTE JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com Sales and trading 7 a.m. to 7 p.m. ET,
More informationPhotocure ASA Executing the Strategy
Photocure ASA Executing the Strategy NOVEMBER 2012 ERIK DAHL, CFO KATHLEEN DEARDORFF, COO Disclaimer The information included in this Presentation contains certain forward-looking statements that address
More informationSPECIALTY MEDICAL CANNABIS COMPANY
SPECIALTY MEDICAL CANNABIS COMPANY TSX Venture: RVV OTCQB: RVVTF Corporate Presentation - August 2018 ReviveThera.com Revive Therapeutics Ltd. Office: 905-605-5535 E-mail: info@revivethera.com Forward
More informationFor personal use only
AusCann Makes Major Progress Towards Production of Cannabinoid Medicines During FY18 Highlights Undertook comprehensive pharmaceutical development project to create an optimal dosage form cannabinoid medicine
More informationNASDAQ: PBMD, ASX: PRR
NASDAQ: PBMD, ASX: PRR Notice: Forward Looking Statements The purpose of the presentation is to provide an update of the business of Prima BioMed Ltd ACN 009 237 889 (ASX:PRR; NASDAQ:PBMD). These slides
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationFor personal use only
ASX Release Oventus presentation for AGM of Thorney Technologies Ltd Brisbane, Australia 24 th November 2017: Oventus Medical Ltd (ASX: OVN) is pleased to release a copy of the presentation that Founder
More informationDendrimer-Oxaliplatin shows better anti-cancer efficacy and less toxicity
Dendrimer-Oxaliplatin shows better anti-cancer efficacy and less toxicity Melbourne, Australia; Wednesday 11 September 2013: Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced it had achieved
More informationDeveloping Xanamem for Alzheimer s Dementia
Developing Xanamem for Alzheimer s Dementia Dr. Bill Ketelbey CEO, Actinogen Medical Investor Presentation March 2015 Forward Statements This presentation has been prepared by Actinogen Limited. ( Actinogen
More informationFor personal use only
28 May 2015 PYL AND MMJ ON TRACK FOR REVENUES IN JULY Highlights: Production of MMJ s GMP-produced CBD food supplement capsules commenced 25 May 2015 Capsules to be branded and sold as Sativol TM Sativol
More informationMEDICAL CANNABIS COMPANY
MEDICAL CANNABIS COMPANY TSX Venture: RVV OTCQB: RVVTF Corporate Presentation - June 2018 ReviveThera.com Revive Therapeutics Ltd. Office: 905-605-5535 E-mail: info@revivethera.com Forward looking statements
More informationPHYTOTECH, FIRST MEDICAL CANNABIS COMPANY TO LIST ON THE ASX
22 January 2015 PHYTOTECH, FIRST MEDICAL CANNABIS COMPANY TO LIST ON THE ASX Highlights Led by a highly qualified, specialised and experienced medical and corporate team First medical grade cannabis company
More informationSPECIALTY MEDICAL CANNABIS COMPANY
SPECIALTY MEDICAL CANNABIS COMPANY TSX Venture: RVV OTCQB: RVVTF Corporate Presentation - August 2018 ReviveThera.com Revive Therapeutics Ltd. Office: 905-605-5535 E-mail: info@revivethera.com Forward
More informationADM to Acquire Neovia and Probiotics International Limited. July 2, 2018
ADM to Acquire Neovia and Probiotics International Limited July 2, 2018 Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates
More informationTruScreen Annual Meeting
TruScreen Annual Meeting September 2018 Shareholders Address FY18 ANNUAL MEETING SHAREHOLDERS ADDRESS 27 SEPTEMBER 2018 INTRODUCTION Welcome to the 2018 AGM. FY18 HIGHLIGHTS 2018 was a year of significance
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
More informationAcasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019
Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019 Planned Enrollment targets achieved in both TRILOGY studies with over 74% of patients randomized at more than 150 clinical sites
More informationA GLOBAL LEADER IN PERSONALIZED NUTRITION
A GLOBAL LEADER IN PERSONALIZED NUTRITION Forward Looking Statements Management will make forward-looking statements during this presentation. Actual results could differ from those projected in such forward-looking
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More informationInvestor Presentation September Cogstate Ltd. All rights reserved.
Investor Presentation September 2017 2017 Cogstate Ltd. All rights reserved. We believe that brain health is profoundly important to quality of life and should be easier to measure. That s why we so passionately
More informationH. LUNDBECK A/S. Teleconference. 10 August PM CET. Financial results Second quarter 2011
H. LUNDBECK A/S Teleconference 10 August 2011-2PM CET Financial results Second quarter 2011 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts
More informationN a s d a q : I N S Y
N a s d a q : I N S Y 0 Safe Harbor Statement This presentation contains both historical information and forward-looking statements. Forward-looking statements are based on management's current expectations
More informationPartnering for Growth
Partnering for Growth JP Morgan Healthcare Conference Simon Lowth, Chief Financial Officer, AstraZeneca 9 January 2013 Partnering for Growth Agenda Our platforms for growth Partnering strategy and capabilities
More informationFor personal use only
Investor Update - March 2017 DISCLAIMER This presentation has been prepared by MGC Pharmaceuticals Limited ( Company ). It does not purport to contain all the information that a prospective investor may
More informationIntercell and Novartis form world leading strategic partnership to drive vaccines innovation
Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Alliance creates opportunity for two strong innovators to combine development efforts in attractive areas Intercell
More informationDARA Reports Year-End 2012 Financial Results
April 1, 2013 DARA Reports Year-End 2012 Financial Results Company Provides a Commercial Portfolio and Development Pipeline Business Update RALEIGH, NC -- (MARKETWIRE) -- 04/01/13 -- DARA BioSciences,
More informationASX Investor Presentation
ASX Investor Presentation Sydney, Australia Dr Peter Neustadt Executive Chairman and CEO November 2014 Copyright and registered trademark notice ASX Investor Presentation Page 0 Who we are SomnoMed Limited
More informationCOMPANY PRESENTATION JULY Bob Bechard Executive Vice-President Corporate Development & Licensing
COMPANY PRESENTATION JULY 2018 Bob Bechard Executive Vice-President Corporate Development & Licensing Forward Looking Statements Some statements in this release may contain forward-looking information.
More informationAn exciting combination in a high growth, high margin Nutrition category. Name of chairman
An exciting combination in a high growth, high margin Nutrition category 2 Vevey, December 14, 2006 Disclaimer This presentation contains forward looking statements which reflect Management s current views
More informationASX ANNOUNCEMENT CELLMID CEO PRESENTS AT "BROKERS MEET BIOTECH
ASX ANNOUNCEMENT CELLMID CEO PRESENTS AT "BROKERS MEET BIOTECH SYDNEY, Wednesday, 18 September 2013: Cellmid Limited (ASX: CDY) provides the following shareholder update, which will be presented at the
More informationOWC PHARMACEUTICAL RESEARCH OTCQB:OWCP
OWC PHARMACEUTICAL RESEARCH OTCQB:OWCP Disclaimer This document details business information of OWC Pharmaceuticals Research Corp and/or our wholly-owned Israeli subsidiary, One World Cannabis Ltd. (collectively,
More informationAnnual General Meeting 25 October Cogstate Ltd. All rights reserved.
Annual General Meeting 25 October 2017 2017 Cogstate Ltd. All rights reserved. Board of Directors Audit, Risk & Compliance Committee Remuneration & Nomination Committee Martyn Myer Non-Exec Chairman Yes
More informationLeading Cannabinoid Patient Care in Canada. Corporate Presentation July 2017 TSXV: CMM OTCQB: CAMDF
Leading Cannabinoid Patient Care in Canada Corporate Presentation July 2017 TSXV: CMM OTCQB: CAMDF Forward Looking Statements Except for historical information, this presentation contains forward-looking
More informationFor personal use only
Targeted DEP shows sustained superior performance in ovarian cancer model Melbourne, Australia; 2 February 2016: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced the final results of the preclinical
More informationOventus: Innovators in Sleep Apnoea Treatment Investor lunch presentation Tattersall s Club, Brisbane
Oventus: Innovators in Sleep Apnoea Treatment Investor lunch presentation Tattersall s Club, Brisbane February 2018 Twitter: @OventusLtd About Oventus (ASX: OVN) Oventus is commercialising its Airway Technology
More informationAradigm Corporation. A respiratory specialty pharmaceutical company fulfilling unmet needs in pulmonary medicine (ARDM) February 2008
Aradigm Corporation A respiratory specialty pharmaceutical company fulfilling unmet needs in pulmonary medicine (ARDM) February 2008 Safe Harbor Statement This presentation contains forward-looking statements
More informationDelivering high quality, cost effective cannabinoid medicines to patients (ASX:AC8) September 2018
Delivering high quality, cost effective cannabinoid medicines to patients (ASX:AC8) September 2018 Disclaimer This presentation has been prepared by AusCann Group Holdings Ltd ACN 008 095 207 ( Company
More informationBRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook to 2020
BRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook Reference Code: GDMECR0130PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables...
More informationGENETIC TECHNOLOGIES LIMITED DISEASE RISK ASSESSMENT ON A GLOBAL SCALE
GENETIC TECHNOLOGIES LIMITED DISEASE RISK ASSESSMENT ON A GLOBAL SCALE Forward Looking Statements This presentation may contain forward-looking statements within the meaning of Section 27A of the U.S.
More informationEU5 Bariatric Surgery Procedures Outlook to 2020
EU5 Bariatric Surgery Procedures Outlook to 2020 Reference Code: GDMECR0089PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of Figures...
More informationImproving the lives of people with neurological conditions. Annual General Meeting Neurotech International Limited (ASX: NTI) November 2017
Improving the lives of people with neurological conditions Annual General Meeting Neurotech International Limited (ASX: NTI) November 2017 Neurotech Overview Medical device company, focussed on the development
More informationNitrazepam. Nitrazepam Tablets TAJ GROUP PHARMACEUTICAL B U S I N E S S. Generics. Active Ingredients: Each tablet contains 10 mg Nitrazepam
Nitrazepam, Nitrazepam India, Nitrazepam manufacturers India, side effects Nitrazepam manufacturers, Taj Pharma India, Nitrazepam overdose, Nitrazepam drug, Nitrazepam composition, Manufacturing Pharmaceutical,
More informationSupplementary Data of Consolidated Financial Statements for the third quarter ended December 31, 2016
Supplementary Data of Financial Statements for the third quarter ended December 31, 2016 January 31, 2017 NITTO DENKO CORPORATION CONTENTS Page Business 1 Segment Information 2 Segment Information By Geographic
More informationFor personal use only
13 February 2018 Creso reports strong progress with construction of its Canadian medicinal cannabis production facility in Nova Scotia Highlights: Site works at Creso s Canadian medicinal cannabis production
More informationINTRODUCTION TO THE MEDICINES PATENT POOL
www.medspal.org TABLE OF CONTENTS 1. Introduction to the Medicines Patent Pool 2. Background on MedsPaL 3. What patent information is included in MedsPaL? 4. What licensing and data exclusivity information
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationChina Cranio Maxillofacial Fixation (CMF) Market Outlook to 2020
China Cranio Maxillofacial Fixation (CMF) Market Outlook to 2020 Reference Code: GDMECC0079DB Publication Date: March 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2
More informationFor personal use only
Developing high quality, cost effective cannabinoid medicines Investor Presentation March 2019 Disclaimer 3 This presentation has been prepared by AusCann Group Holdings Ltd ACN 008 095 207 ( Company ).
More informationMDxHealth. Strong outlook for Research Note.
Research Note MDxHealth Strong outlook for 2017 Chief Research Analyst Marcel Wijma MSc +1 (917) 460 6185 (US) +31 (6) 8489 2954 (NL) m.wijma@leeuwenhoeck.com http://www.leeuwenhoeck.com Date: 23 February
More informationFor personal use only
ASX ANNOUNCEMENT 22 NOVEMBER 2017 AGM ADDRESSES FROM THE CHAIRMAN & CEO 22 November 2017 Cann Group Limited (ASX: CAN) is pleased to provide the following addresses to be delivered by its Chairman Allan
More informationDealdoc. Licensing, development and marketing agreement for Relenza. Glaxo Wellcome GlaxoSmithKline Biota. Sep
Dealdoc Licensing, development and marketing agreement for Relenza Glaxo Wellcome GlaxoSmithKline Biota Sep 04 2000 Licensing, development and marketing agreement for Relenza Glaxo Wellcome Companies:
More informationFor personal use only
HY18 Result Presentation 13 February 2018 Dig Howitt Brent Cubis CEO & President CFO HY18 Result highlights Strong momentum across developed markets continues Developed market unit growth up 12% Strengthening
More informationPSMA-617 License Transaction. October 2, 2017
PSMA-617 License Transaction October 2, 2017 Forward Looking Statements Certain of the statements made in this presentation are forward looking, such as those, among others, relating to future spending,
More informationNOXOPHARM CORPORATE PRESENTATION FNN SHAW&PARTNERS INVESTOR EVENT ASX: NOX
Date: 14 August, 2018 Sydney, Australia ASX: NOX Noxopharm Limited NOXOPHARM CORPORATE PRESENTATION FNN SHAW&PARTNERS INVESTOR EVENT ABN 50 608 966 123 Registered Office and Operations Office: Suite 3,
More informationPRESENTATION. AGM 27 th OCTOBER 2015 ASX: PAA ACN
PRESENTATION AGM 27 th OCTOBER 2015 ASX: PAA ACN 094 006 023 Disclaimer This presentation does not constitute investment advice. Neither this presentation nor the information contained in it constitutes
More informationStraumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America
Media release Straumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America Group net revenue rises 2% (l.c.) as double-digit increases across America offset
More informationThis document contains certain forward-looking statements, relating to Rhinomed Limited s (Rhinomed) business which can be identified by the use of
BIOSHARES JULY 2016 This document contains certain forward-looking statements, relating to Rhinomed Limited s (Rhinomed) business which can be identified by the use of forward looking terminology such
More information